MDNA - Medicenna Merck enter clinical trial collaboration to evaluate combo cancer treatment

• Medicenna Therapeutics ( NASDAQ: MDNA ) on Tuesday said it had entered into a clinical trial collaboration and supply agreement with Merck ( NYSE: MRK ) to evaluate its agonist in combination with cancer drug Keytruda in its ongoing phase 1/2 study named ABILITY.
• Medicenna's ( MDNA ) agonist, MDNA11, is being assessed in the early- to mid-stage trial as a monotherapy and in combination with MRK's Keytruda to treat patients with cancerous tumors.
• As per the clinical trial collaboration deal, MDNA will sponsor the study and MRK will supply Keytruda.
• "Although we believe that MDNA11 has great potential as a single agent, combining it with Keytruda may significantly enhance therapeutic benefit in different types of cancer, potentially maximizing the value of MDNA11," MDNA CEO Fahar Merchant said in a statement .
• MDNA stock +1.5% to $1.03 in afternoon trading.

For further details see: